{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T10:49:23Z","timestamp":1769510963526,"version":"3.49.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,4,5]]},"DOI":"10.7759\/cureus.57677","type":"journal-article","created":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T18:27:24Z","timestamp":1712341644000},"source":"Crossref","is-referenced-by-count":4,"title":["Abemaciclib-Associated Skin, Hair, and Nail Toxicities: A Case Report"],"prefix":"10.7759","author":[{"given":"Hanadi","family":"Alsatti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Basel","family":"AlMalki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yara","family":"Alghamdi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.102086","article-title":"Comparison of treatment-related adverse events of different cyclin-dependent kinase 4\/6 inhibitors in metastatic breast cancer: a network meta-analysis","volume":"90","author":"Desnoyers A","year":"2020","unstructured":"Desnoyers A, Nadler MB, Kumar V, Saleh R, Amir E. Comparison of treatment-related adverse events of different cyclin-dependent kinase 4\/6 inhibitors in metastatic breast cancer: a network meta-analysis. Cancer Treat Rev. 2020, 90:102086. 10.1016\/j.ctrv.2020.102086","journal-title":"Cancer Treat Rev"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0142","article-title":"Clinical management of potential toxicities and drug interactions related to cyclin-dependent kinase 4\/6 inhibitors in breast cancer: practical considerations and recommendations","volume":"22","author":"Spring LM","year":"2017","unstructured":"Spring LM, Zangardi ML, Moy B, Bardia A. Clinical management of potential toxicities and drug interactions related to cyclin-dependent kinase 4\/6 inhibitors in breast cancer: practical considerations and recommendations. Oncologist. 2017, 22:1039-48. 10.1634\/theoncologist.2017-0142","journal-title":"Oncologist"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-021-00645-0","article-title":"Skin toxicities with cyclin-dependent kinase 4\/6 inhibitors in breast cancer: signals from disproportionality analysis of the FDA Adverse Event Reporting System","volume":"23","author":"Raschi E","year":"2022","unstructured":"Raschi E, Fusaroli M, La Placa M, Ardizzoni A, Zamagni C, Poluzzi E, De Ponti F. Skin toxicities with cyclin-dependent kinase 4\/6 inhibitors in breast cancer: signals from disproportionality analysis of the FDA Adverse Event Reporting System. Am J Clin Dermatol. 2022, 23:247-55. 10.1007\/s40257-021-00645-0","journal-title":"Am J Clin Dermatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3389\/pore.2023.1611115","article-title":"Vitiligo-like lesions induced by cyclin-dependent kinase 4\/6 inhibitor palbociclib: a case report and literature review","volume":"29","author":"Gao S","year":"2023","unstructured":"Gao S, Wei G, Hao Y. Vitiligo-like lesions induced by cyclin-dependent kinase 4\/6 inhibitor palbociclib: a case report and literature review. Pathol Oncol Res. 2023, 29:1611115. 10.3389\/pore.2023.1611115","journal-title":"Pathol Oncol Res"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1093\/omcr\/omac116","article-title":"Ribociclib and palbociclib-induced erythema multiforme: a case report","volume":"2022","author":"Vrana E","year":"2022","unstructured":"Vrana E, Mylona S, Bobos M, Kontovinis L, Papazisis K. Ribociclib and palbociclib-induced erythema multiforme: a case report. Oxf Med Case Reports. 2022, 2022:omac116. 10.1093\/omcr\/omac116","journal-title":"Oxf Med Case Reports"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2021.05.028","article-title":"Subacute cutaneous lupus erythematosus following abemaciclib therapy for metastatic breast cancer","volume":"14","author":"Kurtyka DJ","year":"2021","unstructured":"Kurtyka DJ, Mohebbi AD, Burke KT, Cardis MA. Subacute cutaneous lupus erythematosus following abemaciclib therapy for metastatic breast cancer. JAAD Case Rep. 2021, 14:10-2. 10.1016\/j.jdcr.2021.05.028","journal-title":"JAAD Case Rep"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1177\/10781552231185855","article-title":"Subacute cutaneous lupus erythematosus following ribociclib therapy for metastatic breast cancer","volume":"29","author":"Collada S\u00e1nchez VL","year":"2023","unstructured":"Collada S\u00e1nchez VL, \u00c1lvarez Criado J, Martinez Martin V, et al.. Subacute cutaneous lupus erythematosus following ribociclib therapy for metastatic breast cancer. J Oncol Pharm Pract. 2023, 29:1793-6. 10.1177\/10781552231185855","journal-title":"J Oncol Pharm Pract"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1177\/1203475417752369","article-title":"Subacute cutaneous lupus erythematosus induced by palbociclib","volume":"22","author":"Pinard J","year":"2018","unstructured":"Pinard J, Patel M, Granter SR, Vleugels RA, Merola JF. Subacute cutaneous lupus erythematosus induced by palbociclib. J Cutan Med Surg. 2018, 22:341-3. 10.1177\/1203475417752369","journal-title":"J Cutan Med Surg"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/cup.13673","article-title":"Subacute cutaneous lupus erythematosus with positive anti-Ro antibodies following palbociclib and letrozole treatment: a case report and literature review","volume":"47","author":"Russell-Goldman E","year":"2020","unstructured":"Russell-Goldman E, Nazarian RM. Subacute cutaneous lupus erythematosus with positive anti-Ro antibodies following palbociclib and letrozole treatment: a case report and literature review. J Cutan Pathol. 2020, 47:654-8. 10.1111\/cup.13673","journal-title":"J Cutan Pathol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.28948","article-title":"Subacute cutaneous lupus erythematosus induced by palbociclib","volume":"14","author":"Salusti-Simpson M","year":"2022","unstructured":"Salusti-Simpson M, Porter H, Morley K. Subacute cutaneous lupus erythematosus induced by palbociclib. Cureus. 2022, 14:e28948. 10.7759\/cureus.28948","journal-title":"Cureus"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-021-01071-1","article-title":"Emerging skin toxicities in patients with breast cancer treated with new cyclin-dependent kinase 4\/6 inhibitors: a systematic review","volume":"44","author":"Silvestri M","year":"2021","unstructured":"Silvestri M, Cristaudo A, Morrone A, et al.. Emerging skin toxicities in patients with breast cancer treated with new cyclin-dependent kinase 4\/6 inhibitors: a systematic review. Drug Saf. 2021, 44:725-32. 10.1007\/s40264-021-01071-1","journal-title":"Drug Saf"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-023-07217-2","article-title":"Multi-center retrospective review of vitiligo-like lesions in breast cancer patients treated with cyclin-dependent kinase 4 and 6 inhibitors","volume":"204","author":"Bang AS","year":"2024","unstructured":"Bang AS, Fay CJ, LeBoeuf NR, et al.. Multi-center retrospective review of vitiligo-like lesions in breast cancer patients treated with cyclin-dependent kinase 4 and 6 inhibitors. Breast Cancer Res Treat. 2024, 204:643-7. 10.1007\/s10549-023-07217-2","journal-title":"Breast Cancer Res Treat"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/239782-abemaciclib-associated-skin-hair-and-nail-toxicities-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T18:27:28Z","timestamp":1712341648000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/239782-abemaciclib-associated-skin-hair-and-nail-toxicities-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,5]]},"references-count":12,"URL":"https:\/\/doi.org\/10.7759\/cureus.57677","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4,5]]}}}